Literature DB >> 15709050

Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children.

Angela Zacharasiewicz1, Nicola Wilson, Christiane Lex, Edward M Erin, Albert M Li, Trevor Hansel, Mohammed Khan, Andrew Bush.   

Abstract

The use of noninvasive methods of monitoring airway inflammation, such as exhaled nitric oxide (eNO) and induced sputum, has been shown to improve asthma monitoring and optimize treatment in adult patients with asthma. There is a lack of comparable data in children. Forty children with stable asthma eligible for inhaled steroid reduction were reviewed every 8 weeks, and their inhaled steroid dose halved if clinically indicated. eNO, sputum induction combined with bronchial hyperreactivity testing, and exhaled breath condensate collection were performed at each visit to predict success or failure of reduction of inhaled steroids. Thirty of 40 (75%) children tolerated at least one dose reduction, 12 of 40 (30%) were successfully weaned off, and in total, 15 of 40 (38%) children experienced loss of asthma control. Treatment reduction was successful in all children who had no eosinophils in induced sputum before the attempted reduction. Using multiple logistic regression, increased eNO (odds ratio, 6.3; confidence interval, 3.75-10.58) and percentage of sputum eosinophils (odds ratio, 1.38; confidence interval, 1.06-1.81) were significant predictors of failed reduction. These findings suggest that monitoring airway inflammation may be useful in optimizing treatment in children with asthma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709050     DOI: 10.1164/rccm.200409-1242OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  51 in total

Review 1.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

Review 2.  Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma.

Authors:  Jiangtao Lin; Kaisheng Yin; Nan Su; Mao Huang; Chen Qiu; Chuntao Liu; Shaoxi Cai; Chuangli Hao
Journal:  Ann Transl Med       Date:  2015-11

Review 3.  Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma.

Authors:  Jiangtao Lin; Kaisheng Yin; Nan Su; Mao Huang; Chen Qiu; Chuntao Liu; Shaoxi Cai; Chuangli Hao
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

Review 4.  Role of interleukin-13 in asthma.

Authors:  Jonathan Corren
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

5.  Associations of Fraction of Exhaled Nitric Oxide with Beta Agonist Use in Children with Asthma.

Authors:  Adam J Spanier; Robert S Kahn; Richard Hornung; Michelle Lierl; Bruce P Lanphear
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-03       Impact factor: 1.349

Review 6.  How has research in the last five years changed my clinical practice?

Authors:  A Bush
Journal:  Arch Dis Child       Date:  2005-08       Impact factor: 3.791

Review 7.  Highlights in asthma 2005.

Authors:  J L Heraghty; A J Henderson
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

8.  [Guideline for the treatment of bronchial asthma in children and adolescents].

Authors:  Josef Riedler; Ernst Eber; Thomas Frischer; Manfred Götz; Elisabeth Horak; Maximilian Zach
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

9.  Longitudinal relationship between sputum eosinophils and exhaled nitric oxide in children with asthma.

Authors:  Louise Fleming; Lemonia Tsartsali; Nicola Wilson; Nicolas Regamey; Andrew Bush
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

10.  Perinatal factors in neonatal and pediatric lung diseases.

Authors:  Rodney D Britt; Arij Faksh; Elizabeth Vogel; Richard J Martin; Christina M Pabelick; Y S Prakash
Journal:  Expert Rev Respir Med       Date:  2013-10-03       Impact factor: 3.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.